Silence Therapeutics plc (NASDAQ:SLN) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Silence Therapeutics plc (NASDAQ:SLN) have received an average rating of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $45.00.

A number of brokerages have recently weighed in on SLN. William Blair restated an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. Chardan Capital restated a “buy” rating and set a $55.00 target price on shares of Silence Therapeutics in a report on Tuesday, December 10th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Silence Therapeutics in a report on Monday, December 2nd. The Goldman Sachs Group began coverage on shares of Silence Therapeutics in a research report on Tuesday, February 11th. They issued a “sell” rating and a $6.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a research report on Wednesday, January 29th.

Institutional Investors Weigh In On Silence Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of SLN. Woodline Partners LP boosted its position in Silence Therapeutics by 22.6% during the fourth quarter. Woodline Partners LP now owns 498,732 shares of the company’s stock worth $3,431,000 after acquiring an additional 91,829 shares during the last quarter. Two Sigma Advisers LP lifted its stake in shares of Silence Therapeutics by 18.6% during the 4th quarter. Two Sigma Advisers LP now owns 98,800 shares of the company’s stock worth $680,000 after purchasing an additional 15,500 shares during the period. Redmile Group LLC boosted its holdings in shares of Silence Therapeutics by 26.3% during the fourth quarter. Redmile Group LLC now owns 2,399,317 shares of the company’s stock worth $16,507,000 after purchasing an additional 500,000 shares during the last quarter. Point72 Asset Management L.P. grew its position in shares of Silence Therapeutics by 35.3% in the fourth quarter. Point72 Asset Management L.P. now owns 633,100 shares of the company’s stock valued at $4,356,000 after purchasing an additional 165,300 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Silence Therapeutics by 50.5% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 128,990 shares of the company’s stock valued at $887,000 after purchasing an additional 43,289 shares during the last quarter. 98.73% of the stock is currently owned by hedge funds and other institutional investors.

Silence Therapeutics Price Performance

NASDAQ SLN opened at $4.77 on Thursday. The business has a 50 day moving average price of $5.71 and a 200 day moving average price of $11.94. The company has a market capitalization of $142.77 million, a P/E ratio of -3.04 and a beta of 1.05. Silence Therapeutics has a 1-year low of $4.06 and a 1-year high of $27.72.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.